71 patents
Utility
CorrectedAcylated GLP-1/GLP-2 Dual Agonists
21 Dec 23
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided.
Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
Filed: 7 Jun 22
Utility
Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
21 Dec 23
The present invention relates to pharmaceutical compositions comprising particular preservatives.
Jesper Skodborg Villadsen, Lise Giehm
Filed: 16 Dec 21
Utility
Cyclic Peptides Multimers Targeting ALPHA-4-BETA-7 Integrin
21 Dec 23
There is described herein, multimers comprising a plurality of compounds covalently linked together, the compounds independently being of formula (I).
Mohammed Monzur MORSHED, Sai Kumar CHAKKA, Jennifer L. HICKEY, Manuel Perez VAZQUEZ, Andrew ROUGHTON, Adam Paul KAFAL, Narendrakumar B. PATEL
Filed: 8 Jun 23
Utility
GIP agonist compounds and methods
14 Nov 23
The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
Filed: 2 Apr 21
Utility
Glucagon analogues
24 Oct 23
The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia.
Ditte Riber, Lise Giehm
Filed: 11 Sep 19
Utility
Kv1.3 blockers
10 Oct 23
The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
Filed: 24 Feb 22
Utility
Compounds Targeting ALPHA4-BETA7 Integrin
21 Sep 23
Abstract: Compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, are described.
Andrew Roughton, Narendrakumar Patel, Adam Paul Kafal, Manuel Perez Vazquez, Jennifer Hickey, Sai Kumar Chakka, Monzur Morshed
Filed: 25 Jun 21
Utility
Cyclic peptides multimers targeting α-4-β-7 integrin
1 Aug 23
Mohammed Monzur Morshed, Sai Kumar Chakka, Jennifer L. Hickey, Manuel Perez Vazquez, Andrew Roughton, Adam Paul Kafal, Narendrakumar B. Patel
Filed: 19 Apr 21
Utility
Pharmaceutical Parenteral Composition of Dual GLP1/2 Agonist
6 Jul 23
The present invention relates to pharmaceutical compositions suitable for parenteral administration in human subjects.
Lise Giehm, Alistair Vincent Gordon Edwards
Filed: 12 Jun 20
Utility
GLP-1/GLP-2 Dual Agonists
27 Apr 23
The invention relates to a composition comprising a GLP-1/GLP-2 dual agonist for use in the treatment of a patient receiving parenteral nutrition.
Jonathan Griffin, Per-Olof Eriksson, Wayne Russell, Jolanta Skarbaliene
Filed: 29 Mar 21
Utility
Agonist Combination
13 Apr 23
The present invention relates to an agonist combination comprising a GLP-1 agonist and a GLP-2 agonist, for use in the treatment of a patient who has undergone surgical resection of the bowel.
Jonathan Griffin, Per-Olof Eriksson, Wayne Russell, Mark Berner-Hansen
Filed: 29 Mar 21
Utility
Acylated GLP-1/GLP-2 Dual Agonists
5 Jan 23
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided.
Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
Filed: 7 Jun 22
Utility
Fluid Delivery and Measurement Systems and Methods
6 Oct 22
Embodiments of this invention relate to a fluid delivery device.
Robert R. Gonnelli, Steven F. Levesque, David Lipson, Peter F. Marshall
Filed: 16 Jun 22
Utility
Adapter for a Fluid Transfer Device
22 Sep 22
An adapter (650) for transferring fluid between a first device (100) and a second device (800).
Christopher GREGORY, Michael BARENBOYM
Filed: 5 Aug 20
Utility
Formulations of GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) Analogues
25 Aug 22
Liquid formulations of GLP-2 analogues that make them suitable for long term storage as liquids and/or that makes them especially suitable for delivery by a drug delivery device are described.
Lise GIEHM, Claes MELANDER, Eva Horn MØLLER
Filed: 27 Sep 19
Utility
KV1.3 Blockers
11 Aug 22
The present invention provides novel blockers of the potassium channel Kv1.3, polynucleotides encoding them, and methods of making and using them.
Henrik Fischer Munch, Rasmus Bugge Jensen, Jens Kvist Madsen
Filed: 24 Feb 22
Utility
Pharmaceutical Composition for Subcutaneous Administration
4 Aug 22
This application concerns pharmaceutical compositions comprising cannabinoids which are suitable for subcutaneous administration in human subjects.
Erick Lucera, Jessica Barnes, Joseph Saldanha
Filed: 15 Jul 20
Utility
Acylated GLP-1/GLP-2 dual agonists
26 Jul 22
A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided.
Bjarne Due Larsen, Jonathan Griffin, Lise Giehm, Alistair Vincent Gordon Edwards
Filed: 6 Apr 20
Utility
Amylin analogues
12 Jul 22
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes.
Jesper Mosolff Mathiesen, Jesper Skodborg Villadsen, Lise Giehm, Henrik Kofoed Munch, Dieter Wolfgang Hamprecht, Alexander Heim-Riether, Giacomo Fossati
Filed: 25 Oct 19
Utility
Pharmaceutical Parenteral Composition of Dual GLP1/2 Agonist
30 Jun 22
The present invention relates to pharmaceutical compositions suitable for parenteral administration in human subjects.
Lise Giehm, Alistair Vincent Gordon Edwards
Filed: 12 Jun 20